Neurocrine Stock
StockStockPrice
Frequently asked questions
What is Neurocrine's market capitalization?
What is Neurocrine's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Neurocrine?
What are the analyst ratings and target price for Neurocrine's stock?
What is Neurocrine's revenue over the trailing twelve months?
What is the EBITDA for Neurocrine?
What is the free cash flow of Neurocrine?
What is the 5-year beta of Neurocrine's stock?
How many employees does Neurocrine have, and what sector and industry does it belong to?
What is the free float of Neurocrine's shares?
Financials
Market Cap
$12.88B5Y beta
0.34EPS (TTM)
$3.734Free Float
99.60MP/E ratio (TTM)
34.06Revenue (TTM)
$2.24BEBITDA (TTM)
$614.00MFree Cashflow (TTM)
$440.10MPricing
Analyst Ratings
The price target is $160.52 and the stock is covered by 25 analysts.
Buy
20
Hold
4
Sell
1
Information
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
1,700
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker